ಸುದ್ದಿ
GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...
The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with ...
GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...
2ದಿ
InvestorsHub on MSNGoodRx Shares Surge After Novo Nordisk Collaboration on $499 Monthly Ozempic and Wegovy
GoodRx (NASDAQ:GDRX) jumped 18% after revealing a partnership with Novo Nordisk (NYSE:NVO) to offer Ozempic and Wegovy to ...
Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...
The Consumer Product Safety Commission issues a warning about fake Labubu dolls posing a choking risk. The FTC is suing a ticket resale company. Former President Jimmy Carter is honored with a postage ...
GoodRx will sell Wegovy and Ozempic at US$499 monthly to eligible self-paying patients. Read more at straitstimes.com. Read ...
GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.
What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.
Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...
ಕೆಲವು ಫಲಿತಾಂಶಗಳನ್ನು ಮರೆಮಾಡಲಾಗಿದೆ ಏಕೆಂದರೆ ನೀವು ಅವುಗಳನ್ನು ಪ್ರವೇಶಿಸಲು ಸಾಧ್ಯವಾಗದಿರಬಹುದು.
ಪ್ರವೇಶಿಸಲಾಗದ ಫಲಿತಾಂಶಗಳನ್ನು ತೋರಿಸಿ